focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRBS.L Regulatory News (RBS)

  • There is currently no data for RBS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Partial Sale of Citizens Financial Group, Inc.

29 Jul 2015 07:01

RNS Number : 3960U
Royal Bank of Scotland Group PLC
29 July 2015
 



29 July 2015

Partial Sale of Citizens Financial Group, Inc. Stake

Further to the announcement by The Royal Bank of Scotland Group plc ("RBSG") on 28 July 2015, RBSG today announces the final pricing of the offering of shares in Citizens Financial Group, Inc. ("CFG" or "Citizens") ("the Offering").

The Offering comprises 86 million shares, or 16.0%, of Citizens common stock at a public offering price per share of $26.00.

RBSG has also granted a 15% over-allotment option, under which the underwriters have a 30-day option to purchase an additional 12.9 million shares at the public offering price, less the underwriting discount. If the underwriters exercise this option in full, the total offering size, including the shares pursuant to the over-allotment option, would comprise 98.9 million shares, or 18.4% of Citizens common stock.

Gross proceeds realised by RBSG will be $2.2 billion ($2.6 billion assuming exercise in full of the over-allotment option) with the cash proceeds being used for general business purposes.

Concurrent to the Offering, Citizens also intend to repurchase a further 9.6 million shares ($250m) of CFG common stock from RBSG at the Offering price in a directed buy back.

Following the Offering and the directed buy back, RBSG will continue to hold up to 23.4% of CFG's shares of common stock (20.9% assuming exercise of the entire over-allotment option), which are subject to a 60 day lock-up. During this period, the lock-up agreement is subject to modification, waiver or cancellation.

RBSG will no longer consolidate CFG in its financial statements, recognising an estimated £1.1 billion gain upon deconsolidation (including £0.9 billion reclassified from equity). RBSG will however continue to fully consolidate Citizens for regulatory reporting purposes as it will retain certain veto rights notwithstanding the reduction in its interest in CFG. Therefore, RBSG will continue to include the Risk-Weighted Assets ("RWAs") of CFG in its consolidated RWAs at the current time.

The partial sale is part of RBSG's strategy to fully exit its holding in CFG as part of its European Commission state aid commitments.

Commenting on today's announcement, RBS Chief Executive Officer, Ross McEwan said:

"The sale of Citizens is an integral part of our capital plan. It will help us to create a simpler, stronger and more efficient UK-focussed bank that can better serve the needs of its customers.

"This offering will leave us owning just over 20% of Citizens. We are now targeting to be able to exit Citizens fully by the end of 2015, a year ahead of the original deadline."

 

Notes:

Citizens Financial Group, Inc. is the 13th largest retail bank holding company in the United States(1), with $137.3 billion in assets as of 30 June 2015. Headquartered in Providence, Rhode Island, the company offers a broad range of retail and commercial banking products and services to individuals, small businesses, middle-market companies, large corporations and institutions. The CFG executive team is led by Bruce Van Saun, Chairman and CEO.

For the financial year ended 31 December 2014 Citizens Financial Group reported a U.S. GAAP profit before income tax of $1,268 million.

Morgan Stanley and Goldman, Sachs & Co are acting as global coordinators and joint book-running managers, and J.P. Morgan and Citigroup are acting as joint book-running managers for this offering. Additionally, Bank of America Merrill Lynch, Credit Suisse, Deutsche Bank Securities, RBS, UBS and Wells Fargo Securities, are also acting as joint book-running managers.

The prospectus relating to the offering may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, Second Floor, New York, New York 10014; Goldman Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone: 1-866-471-2526 or via email: prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone: 866-803-9204; and Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone: 800-831-9146

The registration statement relating to these securities has been filed and has been declared effective by the Securities and Exchange Commission.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

For further information please contact:

Investors

 

Richard O'Connor

Head of Investor Relations

+44 (0) 207 672 1758

Media

 

RBS Press Office

+44 (0) 131 523 4205

 

(1) According to SNL Financial, as at 31st March 2015

 

This announcement contains forward looking statements with respect to the business, strategy and plans of RBS and its current goals and expectations relating to its future financial condition and performance. Statements that are not historical facts, including statements about RBS or RBS management's beliefs and expectations, are forward looking statements. By their nature, forward looking statements involve risk and uncertainty because they relate to future events and circumstances that will or may occur. RBS' actual future business, strategy, plans and/or results may differ materially from those expressed or implied in these forward looking statements as a result of a variety of factors. Please refer to the latest Annual Report on Form 20-F filed with the US Securities and Exchange Commission for a discussion of certain factors together with examples of forward looking statements. The forward looking statements contained in this announcement are made as at the date of this announcement, and RBS undertakes no obligation to update any of its forward looking statements.

 

.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLIFEEDEIAFIE
Date   Source Headline
17th Mar 20205:24 pmRNSDirectorate Change
17th Mar 20204:42 pmRNSSecond Price Monitoring Extn
17th Mar 20204:38 pmRNSPrice Monitoring Extension
17th Mar 20208:30 amRNSMorgan Stanley European Financials Conference
16th Mar 20205:14 pmRNSNatWest Markets N.V. 2019 ARA
10th Mar 20204:51 pmRNSDirector/PDMR Shareholding
2nd Mar 20202:34 pmRNSDirector/PDMR Shareholding
28th Feb 20204:29 pmRNSCorrection of Dividend Declaration
28th Feb 20201:58 pmRNSTotal Voting Rights and Capital
28th Feb 20207:00 amRNSFiling of Annual Report on Form 20-F with US SEC
27th Feb 20209:55 amRNSBlock Listing Cancellation
24th Feb 202012:40 pmRNSDividend Declaration
20th Feb 20204:10 pmRNSHolding(s) in Company
14th Feb 20203:58 pmRNSRBSG ENTM Publication of Suppl.Prospcts
14th Feb 20207:01 amRNSAnnual Financial Report
14th Feb 20207:00 amRNSFinal Results
31st Jan 20202:12 pmRNSTotal Voting Rights and Capital
30th Jan 20203:57 pmRNSDirector/PDMR Shareholding
16th Jan 20202:08 pmRNSForm 8.3 - Accesso Technology Group plc
2nd Jan 20201:58 pmRNSForm 8.3 - Accesso Technology Group plc
31st Dec 20191:10 pmRNSDirector/PDMR Shareholding
31st Dec 201911:20 amRNSTotal Voting Rights and Capital
30th Dec 20193:02 pmRNSForm 8.3 - Accesso Technology Group plc
20th Dec 20197:00 amRNSPublication of Suppl.Prospcts replacement
19th Dec 20195:40 pmRNSPublication of Suppl.Prospcts
19th Dec 20197:00 amRNSNatWest Markets Change in Executive Directors
16th Dec 20195:47 pmRNS2019 Bank of England stress test results
4th Dec 201912:34 pmRNSForm 8.3 - Accesso Technology Group plc
2nd Dec 20195:34 pmRNSPublication of Suppl.Prospcts
29th Nov 20192:20 pmRNSDirector/PDMR Shareholding
29th Nov 20191:28 pmRNSAnnouncement of NatWest Markets N.V. Transfer
29th Nov 201912:01 pmRNSTotal Voting Rights and Capital
27th Nov 201911:56 amRNSDividend Declaration
21st Nov 20196:26 pmRNSPublication of a Prospectus
21st Nov 201910:45 amRNSReduction in Pillar 2A capital requirements
14th Nov 201911:23 amRNSPublication of Final Terms
13th Nov 20193:00 pmRNSForm 8.3 - Accesso Technology Group plc
8th Nov 20193:00 pmRNSDirector/PDMR Shareholding
1st Nov 20194:12 pmRNSDirector/PDMR Shareholding
31st Oct 20193:30 pmRNSDirector/PDMR Shareholding
31st Oct 20192:08 pmRNSTotal Voting Rights and Capital
30th Oct 20199:38 amRNSRBSG pricing of US$750mn of Subordinated Notes
25th Oct 20195:22 pmRNSPublication of Suppl.Prospcts
24th Oct 20197:00 amRNSQ3 Interim Management Statement
16th Oct 20192:54 pmRNSForm 8.3 - Accesso Technology Group plc
8th Oct 201911:35 amRNSBlock Listing Six Monthly Return
3rd Oct 20191:08 pmRNSPublication of Final Terms
1st Oct 20195:29 pmRNSDirector/PDMR Shareholding
30th Sep 20193:28 pmRNSTotal Voting Rights
24th Sep 20198:30 amRNSBank of America Merrill Lynch Annual Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.